Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 2/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14570472 | 1.00 | TAAR1 (0.65) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL5309205 | 0.99 | TAAR1 (0.63) | TAAR1HTR2A | |
| Hydrochloric Acid SCHEMBL5309198 | 0.99 | TAAR1 (0.63) | TAAR1HTR2A | |
| SCHEMBL8282635 | 0.80 | CYP3A4 (0.51) | TAAR1HTR2A | |
| SCHEMBL1740704 | 0.80 | TAAR1 (1.00) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL1740705 | 0.80 | TAAR1 (1.00) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL31063152 | 0.80 | DPP4 (0.42) | TAAR1 | |
| SCHEMBL31456004 | 0.79 | HMGCR (0.49) | TAAR1 | |
| Hydrochloric Acid SCHEMBL29844954 | 0.78 | TAAR1 (0.96) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL31455983 | 0.78 | CA1 (0.51) | TAAR1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007038372-A1 | PHENYLETHYLAMINE ANALOGS AND THEIR USE FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2007-04-05 | — | — | WO | disclosed |
| US-20070072920-A1 | Phenylethylamine analogs and their use for treating glaucoma | ALCON, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072920-A1 | Phenylethylamine analogs and their use for treating glaucoma | PNMT, PIGO, PDE2A | TAAR1 565/4885HTR2A 514/4885HTR1A 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.